Heart failure is a growing health problem in the Western world; death due to severe heart failure has more than tripled in recent years. Whereas heart transplant is the gold standard for treatment, many countries experience a shortage of donors simultaneously with sharp increase in prevalence. “Bridge to transplant” and “lifelong” therapy with Left Ventricular Assist Devices (LVADs) have therefore emerged as treatment. Prolonged treatment with LVAD increases risk for thromboembolic complications, such as pump thromboses and stroke. Successful LVAD treatment depends on early detection of such events, but current methods are highly uncertain and inadequate. We can provide a solution to this clinically important problem by a continuous and automated accelerometer-based surveillance method. Accelerometers are commodity equipment, and their small size allows easy integration into VAD pumps.
Our solution will reduce hospital costs and the overall safety and quality of life for the patients will be improved as LVAD failure and ischemic stroke due to clotting/thrombus formations and embolism can be avoided. Mortality, complications; re-hospitalization, hospital controls, and medication will be reduced.
Inven2 seeks development partners and/or licensees for the technology.
Researchers at Oslo University Hospital have developed a method with an accelerometer attached to an LVAD. Through continuous measurements of vibrations and frequency analysis, the patient is surveilled automatically in real time, greatly improving the diagnosis and evaluation of LVAD complications and function. The method has proven to detect thrombus sizes down to 0.1 ml, where there were no changes in the built-in alarm mechanism in the LVAD device based on energy consumption, which is the key parameter in LVAD function monitoring today. Our technology can differentiate different thromboembolic events and monitor the hemodynamic status of the patient.
Continuous and automatic surveillance mitigating severe LVAD events.
Pending patent WO2014/207225